CD123, the alfa-subunit of the interleukin-3 (IL-3) receptor, is an attractive target, which has been reported to be expressed by the majority of AML patients, both on bulk leukemic cells and CD34+CD38− putative LSCs [14,15]. The gene discussed is CD38; the disease is acute myeloid leukemia.